eli lilly glp-1 drugs to seek approval of new weight-loss drug this year Novo Nordisk vs Eli Lilly:

As demonstrated in healthy human volunteers, GLP-1 infusion acutely increases blood flow in the subcutaneous abdominal adipose tissue and skeletal muscle without alterations in splanchnic blood flow [650]

Additional exclusion considerations in clinical research design: Severe renal impairment (eGFR below 30 mL/min/1.73m2)

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

In some cases, this leads to therapeutic compromises, where treatment decisions are shaped by access rather than optimal efficacy

Expectations are high for the unveiling of newer drugs in the future

It reduces appetite by targeting brain areas that control hunger, slows gastric emptying to extend feelings of fullness, and improves insulin sensitivity